Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDARA Takes Effect With Under-The-Radar Presidential Signature

Aug 19 2017

• By Derrick Gingery

White House

Related Content

FDA Gives Congress Reprieve On Deadline For Passing User Fee Bill

Jul 26 2017

White House Slams Generic Exclusivity Provisions In User Fee Bill

Jul 14 2017

Who Speaks For The White House On Drug Prices? Industry Better Hope It Is Not Donald Trump

Mar 14 2017

FDARA: The Forgotten Health Care Bill

Aug 19 2017

Implementing User Fees Should Be Lighter Lift For FDA This Time Around; Bill Heads To White House

Aug 03 2017

FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit

Jun 28 2017

Drug Pricing Hearing In Senate Postponed, Handing Innovators Another Victory

Jun 29 2017

Additional Topics

United States FDA Legislation Drug Review Biosimilars Generic Drugs Review Pathway Policy BioPharmaceutical

More from US FDA

More from Agency Leadership

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window